Clinical Trial: A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07026916) titled 'A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer' on June 03.

Brief Summary: This is a multicenter, open-label, phase II study to explore the efficacy, safety/tolerability and pharmacokinetics (PK) of GFH375 in in Patients with Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Metastatic Pancreatic Cancer

Intervention: DRUG: GFH375

GFH375 will be administered at the 600mg QD, orally, until disease progression or intolerable toxicity.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Genfleet Therap...